Annual CFF
-$7.91 M
-$119.22 M-107.11%
December 31, 2023
Summary
- As of February 6, 2025, TRVI annual cash flow from financing activities is -$7.91 million, with the most recent change of -$119.22 million (-107.11%) on December 31, 2023.
- During the last 3 years, TRVI annual CFF has fallen by -$24.63 million (-147.31%).
- TRVI annual CFF is now -107.11% below its all-time high of $111.31 million, reached on December 31, 2022.
Performance
TRVI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.98 M
-$89.00 K-1.76%
September 30, 2024
Summary
- As of February 6, 2025, TRVI quarterly cash flow from financing activities is $4.98 million, with the most recent change of -$89.00 thousand (-1.76%) on September 30, 2024.
- Over the past year, TRVI quarterly CFF has increased by +$5.03 million (+9318.52%).
- TRVI quarterly CFF is now -92.16% below its all-time high of $63.50 million, reached on June 30, 2019.
Performance
TRVI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$9.96 M
+$3.47 M+53.39%
September 30, 2024
Summary
- As of February 6, 2025, TRVI TTM cash flow from financing activities is $9.96 million, with the most recent change of +$3.47 million (+53.39%) on September 30, 2024.
- Over the past year, TRVI TTM CFF has increased by +$17.87 million (+225.95%).
- TRVI TTM CFF is now -91.99% below its all-time high of $124.40 million, reached on September 30, 2022.
Performance
TRVI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TRVI Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -107.1% | +9318.5% | +225.9% |
| 3 y3 years | -147.3% | +3614.9% | +29.9% |
| 5 y5 years | -318.0% | +3707.3% | -86.4% |
TRVI Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -107.1% | at low | -91.1% | +165.0% | -92.0% | +225.9% |
| 5 y | 5-year | -107.1% | at low | -91.1% | +165.0% | -92.0% | +225.9% |
| alltime | all time | -107.1% | at low | -92.2% | +165.0% | -92.0% | +225.9% |
Trevi Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.98 M(-1.8%) | $9.96 M(+53.4%) |
| Jun 2024 | - | $5.07 M(<-9900.0%) | $6.50 M(-204.2%) |
| Mar 2024 | - | -$28.00 K(-48.1%) | -$6.24 M(-21.2%) |
| Dec 2023 | -$7.91 M(-107.1%) | -$54.00 K(-103.6%) | -$7.91 M(+9.8%) |
| Sep 2023 | - | $1.51 M(-119.7%) | -$7.20 M(-115.5%) |
| Jun 2023 | - | -$7.66 M(+350.0%) | $46.59 M(-57.7%) |
| Mar 2023 | - | -$1.70 M(-361.2%) | $110.23 M(-1.0%) |
| Dec 2022 | $111.31 M(+435.8%) | $652.00 K(-98.8%) | $111.31 M(-10.5%) |
| Sep 2022 | - | $55.30 M(-1.2%) | $124.40 M(+79.7%) |
| Jun 2022 | - | $55.98 M(-9056.5%) | $69.23 M(+332.6%) |
| Mar 2022 | - | -$625.00 K(-104.5%) | $16.00 M(-23.0%) |
| Dec 2021 | $20.77 M | $13.74 M(>+9900.0%) | $20.77 M(+170.8%) |
| Sep 2021 | - | $134.00 K(-95.1%) | $7.67 M(-67.5%) |
| Jun 2021 | - | $2.75 M(-33.6%) | $23.63 M(+13.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $4.15 M(+551.0%) | $20.87 M(+24.8%) |
| Dec 2020 | $16.72 M(-77.2%) | $637.00 K(-96.0%) | $16.72 M(+4.0%) |
| Sep 2020 | - | $16.09 M(<-9900.0%) | $16.08 M(<-9900.0%) |
| Jun 2020 | - | -$12.00 K(<-9900.0%) | -$150.00 K(-100.2%) |
| Mar 2020 | - | $0.00(0.0%) | $63.36 M(-13.5%) |
| Dec 2019 | $73.21 M(+1917.4%) | $0.00(-100.0%) | $73.21 M(+2.1%) |
| Sep 2019 | - | -$138.00 K(-100.2%) | $71.70 M(-12.9%) |
| Jun 2019 | - | $63.50 M(+544.8%) | $82.31 M(+430.1%) |
| Mar 2019 | - | $9.85 M(-753.1%) | $15.53 M(+327.9%) |
| Dec 2018 | $3.63 M(-83.3%) | -$1.51 M(-114.4%) | $3.63 M(-29.4%) |
| Sep 2018 | - | $10.47 M(-419.0%) | $5.14 M(-196.4%) |
| Jun 2018 | - | -$3.28 M(+60.0%) | -$5.33 M(+160.0%) |
| Mar 2018 | - | -$2.05 M | -$2.05 M |
| Dec 2017 | $21.72 M | - | - |
FAQ
- What is Trevi Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Trevi Therapeutics?
- What is Trevi Therapeutics annual CFF year-on-year change?
- What is Trevi Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly CFF year-on-year change?
- What is Trevi Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Trevi Therapeutics?
- What is Trevi Therapeutics TTM CFF year-on-year change?
What is Trevi Therapeutics annual cash flow from financing activities?
The current annual CFF of TRVI is -$7.91 M
What is the all time high annual CFF for Trevi Therapeutics?
Trevi Therapeutics all-time high annual cash flow from financing activities is $111.31 M
What is Trevi Therapeutics annual CFF year-on-year change?
Over the past year, TRVI annual cash flow from financing activities has changed by -$119.22 M (-107.11%)
What is Trevi Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TRVI is $4.98 M
What is the all time high quarterly CFF for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly cash flow from financing activities is $63.50 M
What is Trevi Therapeutics quarterly CFF year-on-year change?
Over the past year, TRVI quarterly cash flow from financing activities has changed by +$5.03 M (+9318.52%)
What is Trevi Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TRVI is $9.96 M
What is the all time high TTM CFF for Trevi Therapeutics?
Trevi Therapeutics all-time high TTM cash flow from financing activities is $124.40 M
What is Trevi Therapeutics TTM CFF year-on-year change?
Over the past year, TRVI TTM cash flow from financing activities has changed by +$17.87 M (+225.95%)